TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000333681
  • Gene Name:BCL2
  • mRNA database:Ensembl
  • mRNA expression :down-regulated
  • mRNA Method:NA
  • mRNA Pathway:apoptotic signaling pathway
  • Evidence:validated
  • (mRNA-drug)

Drug basic information

  • Drug ID:DB13811
  • Drug Name:Oblimersen
  • Drug Method:down-regulated the gene expression the gene expression

Disease basic infommation

  • Disease:non-hodgkin lymphoma
  • Tissue:NA

Other information

  • Title:Targeting the proapoptotic factor Bcl-2 in non-Hodgkin＇s lymphoma
  • Journal:Oncology (Williston Park)
  • Published:2004
  • PubMed ID:15651174
  • Abstract:Bcl-2 functions as a key survival factor for lymphocytes and is highly expressed in a majority of non-Hodgkin＇s lymphomas. The ability of oblimersen sodium (Genasense, previously known as G3139) to target bcl-2 messenger RNA and decrease Bcl-2 protein levels has the potential to enhance the activity of cytotoxic chemotherapy. Pretreatment with oblimersen followed by cyclophosphamide (Cytoxan, Neosar) markedly improved survival relative to single-agent cyclophosphamide in a murine xenograft model. Oblimersen has also enhanced the cytotoxicity of a variety of other agents against non-Hodgkin＇s lymphoma, including etoposide, rituximab (Rituxan), and alemtuzumab (Campath). An initial phase I study of oblimersen in non-Hodgkin＇s lymphoma demonstrated modest single-agent activity. Recent reports suggest that oblimersen may add to the activity of R-CHOP (rituximab-cyclophosphamide/doxorubicin/vincristine/prednisone) in previously untreated mantle cell lymphoma and to rituximab alone in a variety of subtypes of relapsed non-Hodgkin＇s lymphoma. Additional studies in both treatment-naive and relapsed patients will define the role of oblimersen in the treatment of non-Hodgkin＇s lymphoma.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3